Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shih, A. H.
Right arrow Articles by Holland, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shih, A. H.
Right arrow Articles by Holland, E. C.
[Cancer Research 64, 4783-4789, July 15, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Dose-Dependent Effects of Platelet-Derived Growth Factor-B on Glial Tumorigenesis

Alan H. Shih1, Chengkai Dai1, Xiaoyi Hu1, Marc K. Rosenblum2, Jason A. Koutcher3 and Eric C. Holland1,4

1 Departments of Cancer Biology and Genetics; 2 Pathology; 3 Medicine, Radiology, and Medical Physics; and 4 Surgery (Neurosurgery) and Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York

Platelet-derived growth factor (PDGF) is expressed in many different tumors, but its precise roles in tumorigenesis remain to be fully defined. Here, we report on a mouse model that demonstrates dose-dependent effects of PDGF-B on glial tumorigenesis. By removing inhibitory regulatory elements in the PDGFB mRNA, we are able to substantially elevate its expression in tumor cells using a retroviral delivery system. This elevation in PDGF-B production results in tumors with shortened latency, increased cellularity, regions of necrosis, and general high-grade character. In addition, elevated PDGF-B in these tumors also mediates vascular smooth muscle cell recruitment that supports tumor angiogenesis. PDGF receptor (PDGFR) signaling appears to be required for the maintenance of these high-grade characteristics, because treatment of high-grade tumors with a small molecule inhibitor of PDGFR results in reversion to a lower grade tumor histology. Our data show that PDGFR signaling quantitatively regulates tumor grade and is required to sustain high-grade oligodendrogliomas.




This article has been cited by other articles:


Home page
Mol. Biol. CellHome page
C. Beadle, M. C. Assanah, P. Monzo, R. Vallee, S. S. Rosenfeld, and P. Canoll
The Role of Myosin II in Glioma Invasion of the Brain
Mol. Biol. Cell, August 1, 2008; 19(8): 3357 - 3368.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
O. J. Becher, D. Hambardzumyan, E. I. Fomchenko, H. Momota, L. Mainwaring, A.-M. Bleau, A. M. Katz, M. Edgar, A. M. Kenney, C. Cordon-Cardo, et al.
Gli Activity Correlates with Tumor Grade in Platelet-Derived Growth Factor-Induced Gliomas
Cancer Res., April 1, 2008; 68(7): 2241 - 2249.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. B. Hoelzinger, T. Demuth, and M. E. Berens
Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment
J Natl Cancer Inst, November 7, 2007; 99(21): 1583 - 1593.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al.
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Genes & Dev., November 1, 2007; 21(21): 2683 - 2710.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. McConville, D. Hambardzumyan, J. B. Moody, W. R. Leopold, A. R. Kreger, M. J. Woolliscroft, A. Rehemtulla, B. D. Ross, and E. C. Holland
Magnetic Resonance Imaging Determination of Tumor Grade and Early Response to Temozolomide in a Genetically Engineered Mouse Model of Glioma
Clin. Cancer Res., May 15, 2007; 13(10): 2897 - 2904.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. I. Fomchenko and E. C. Holland
Mouse models of brain tumors and their applications in preclinical trials.
Clin. Cancer Res., September 15, 2006; 12(18): 5288 - 5297.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Assanah, R. Lochhead, A. Ogden, J. Bruce, J. Goldman, and P. Canoll
Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses.
J. Neurosci., June 21, 2006; 26(25): 6781 - 6790.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Dresemann
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series
Ann. Onc., October 1, 2005; 16(10): 1702 - 1708.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.